POLYPEPTIDE FROM HETERACTIS MAGNIFICA SEA ANEMONE INHIBITING MAMMALIAN Α-AMYLASES AND ITS USE AS AN INHIBITOR OF MAMMALIAN Α-AMYLASES, AS WELL AS AGENTS FOR THE TREATMENT AND/OR PREVENTION OF POSTPRANDIAL HYPERGLYCEMIA, CORRECTION OF OVERWEIGHT AND OBESITY Russian patent published in 2023 - IPC C07K14/435 C07K19/00 C12N15/62 C12P21/00 A61K38/17 A61P3/04 A61P3/10 

FIELD: biotechnology.

SUBSTANCE: invention relates to a new polypeptide inhibitor of mammalian alpha-amylases, and can be used in medicine for the treatment or prevention of postprandial hyperglycemia, correction of overweight and obesity. A Mgf-II polypeptide from Heteractis magnifica sea anemone is proposed, which has the ability to reduce the level of postprandial glucose in the blood of mammals due to the effective inhibition of alpha-amylases.

EFFECT: invention makes it possible to obtain an effective glucose-lowering drug having a directed action on a molecular target, which can be delivered to the body orally.

5 cl, 9 dwg, 8 ex